{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/leg-ulcer-venous/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"fe306aab-d8d7-5181-a461-128f2aa3c65a","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field 08d5db63-49ab-431f-8bc9-aa9000badb7a --><h2>Erythromycin</h2><!-- end field 08d5db63-49ab-431f-8bc9-aa9000badb7a -->","summary":"","htmlStringContent":"<!-- begin item c2b43311-8475-47e4-90a9-aa9000badb61 --><!-- end item c2b43311-8475-47e4-90a9-aa9000badb61 -->","topic":{"id":"627b2b3c-014b-5543-8f89-0f3ffa6344ad","topicId":"4c5db985-9544-48b2-8c54-8915ec210739","topicName":"Leg ulcer - venous","slug":"leg-ulcer-venous","lastRevised":"Last revised in January 2021","chapters":[{"id":"01818c5e-efb9-59c4-b339-08b834294232","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"313e84c5-8bc7-5150-826a-467ea7252acd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2597db24-8ec5-54d4-86ad-8082be50f4f6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"38f24092-0019-582d-86bf-d1f61bccde1d","slug":"changes","fullItemName":"Changes"},{"id":"cdc15e74-0503-53a5-a4be-c53ec4e20898","slug":"update","fullItemName":"Update"}]},{"id":"73d0cf59-f9c0-5785-8c74-e756826d5d1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"64b11689-d52a-560f-8d9b-c592d654615e","slug":"goals","fullItemName":"Goals"},{"id":"ac3d1637-467f-5edb-8fd8-73f66160080f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bffe5b2-0ce0-5ae8-8c0b-914bb6ed5a1d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"82441da5-60f5-53b4-b510-187f7bacb4a8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3e5817d5-30e7-54b7-b9ba-224b4a295bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b30bb006-efbc-5a69-90f3-30abf232a97d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84dc0da0-8533-5c5d-99f6-7c04a116701a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"45d8d35d-9757-544c-b04e-9747898a1f0e","slug":"definition","fullItemName":"Definition"},{"id":"21acb832-e5e8-5bd1-9b8d-9410ec5011bf","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cf27bd7b-b787-5def-bb40-ee0f134a8aca","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a55a1739-f3d2-534c-b533-f6406d9c81ea","slug":"complications","fullItemName":"Complications"},{"id":"683b612a-3f1d-5580-951b-e14672f52b4a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"dbc94220-a914-56d0-883d-d158da511e1c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"57b3b7a5-9042-53fa-a236-56d0d02b647e","slug":"assessment","fullItemName":"Assessment"},{"id":"35ee8784-602e-5a29-9ccf-65b3c3f940d2","slug":"interpretation-of-abpi","fullItemName":"Interpretation of ABPI"},{"id":"0c766f2c-0c8f-521b-85fd-e947ba6b2d09","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5e199f8a-7621-5318-9da1-264db8f544b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"c8bda10b-ebb6-533b-9c91-96efa5ddf0c3","slug":"venous-leg-ulcers","fullItemName":"Scenario: Venous leg ulcers"}]},{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"66a7f656-c6f5-57a2-a08a-1533a6fd4e92","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"a6cda703-9039-5115-b3d3-478cdb4d1e55","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"1cf75cbb-8bc4-58cc-9a1b-11516db5ad2c","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"3f0efc32-779b-56f6-85ca-e46a59745bed","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"fe306aab-d8d7-5181-a461-128f2aa3c65a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"314a80d5-e16b-5625-8d64-4141535ff392","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"b7e7b8ec-799c-5ea5-9ac0-11935f899b8a","slug":"oral-analgesia","fullItemName":"Oral analgesia"},{"id":"43ed3b03-6322-5690-8f85-b6e10a0b3d3e","slug":"pentoxifylline","fullItemName":"Pentoxifylline"}]},{"id":"19f3ffbe-f365-5196-8586-0dceeaf69908","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"89207239-b8a4-50ce-8b2d-3065a830c0af","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"45831e7c-0e6f-50f3-a513-fe4fcacff65e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3d90cdb0-b2fd-5bfd-bd2d-342e36901f9d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8b66d1a4-6ee5-5556-b671-204219a81787","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8ee442-8da6-524f-bf34-e6a9cc2a771e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6fa96be3-beae-51f6-9f1c-4d278b058d09","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e75dc366-237b-55d2-a654-2e3bf503b955","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"42b1d43d-f9a1-57d5-9c56-ac47122ae0b0","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 56566cab-03e8-43cd-84b2-aa9000bb081d --><h3>What are the contraindications and cautions for erythromycin?</h3><!-- end field 56566cab-03e8-43cd-84b2-aa9000bb081d -->","summary":"","htmlStringContent":"<!-- begin item f189dbb4-27cd-416d-a27e-aa9000bb0802 --><!-- begin field 163a1c3f-6795-49b3-acbb-aa9000bb081d --><ul><li><strong>Do not prescribe erythromycin to people with:</strong><ul><li>Porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul></li><li><strong>Prescribe erythromycin with caution</strong> <strong>to people with:</strong><ul><li>Impaired hepatic function or those taking hepatotoxic drugs — erythromycin is principally excreted by the liver. </li><li>Renal impairment — give a maximum of 1.5 g daily in severe renal impairment (due to the risk of ototoxicity). </li><li>Myasthenia gravis — erythromycin may aggravate weakness symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">MHRA, 2020</a>]</p><!-- end field 163a1c3f-6795-49b3-acbb-aa9000bb081d --><!-- end item f189dbb4-27cd-416d-a27e-aa9000bb0802 -->","subChapters":[]},{"id":"978b3f17-93b0-564f-a5a0-28ddc1bc63cc","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 35262626-242e-4883-b745-aa9000bb1540 --><h3>What are the possible adverse effects of erythromycin?</h3><!-- end field 35262626-242e-4883-b745-aa9000bb1540 -->","summary":"","htmlStringContent":"<!-- begin item d4d2e6a7-eb2c-4122-b90d-aa9000bb1529 --><!-- begin field 7488933e-bc3b-438c-a089-aa9000bb1540 --><ul><li><strong>The most common adverse effects of erythromycin are </strong><strong>gastrointestinal and are dose-related. </strong>They include upper abdominal discomfort, nausea, vomiting, diarrhoea, pancreatitis, and anorexia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018f</a>].<ul><li>Consider pseudomembranous colitis (an acute, exudative colitis caused by <em>Clostridium difficile</em>) if a person develops severe diarrhoea during or after treatment with erythromycin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information.</li></ul></li><li><strong>Reversible hearing loss (sometimes with tinnitus) </strong>can rarely occur after large doses of erythromycin.</li><li><strong>Other adverse effects of </strong><strong>erythromycin</strong><strong> include:</strong><ul><li>Frequency not known — cerebral impairment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 7488933e-bc3b-438c-a089-aa9000bb1540 --><!-- end item d4d2e6a7-eb2c-4122-b90d-aa9000bb1529 -->","subChapters":[]},{"id":"a7b193d0-0154-5206-8128-cd17d72097ad","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3e15c55c-a353-466a-a1cc-aa9000bb2260 --><h3>What are some possible drug interactions of erythromycin?</h3><!-- end field 3e15c55c-a353-466a-a1cc-aa9000bb2260 -->","summary":"","htmlStringContent":"<!-- begin item f4792545-22f8-4bae-b604-aa9000bb2248 --><!-- begin field 444a6d00-c9f4-47ea-9266-aa9000bb2260 --><ul><li><strong>Drug interactions </strong><strong>with erythromycin include:</strong><ul><li><strong>Alprazolam</strong> — erythromycin is predicted to increase the exposure to alprazolam.<ul><li>Manufacturer advises caution.</li></ul></li><li><strong>Aminophylline</strong> — aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of Torsade de pointes) when given with erythromycin.<ul><li>Manufacturer makes no recommendation.</li></ul></li><li><strong>Calcium channel blockers </strong>— erythromycin may increase serum levels of calcium channel blockers metabolized by CYP3A4 (such as verapamil, amlodipine, and diltiazem).<ul><li>Due to an increased risk of adverse effects, particularly hypotension, caution is advised with concurrent use.</li></ul></li><li><strong>Carbamazepine </strong>— erythromycin markedly increases the concentration of carbamazepine, leading to carbamazepine toxicity (which may present as nausea and vomiting, ataxia, and drowsiness).<ul><li>Monitor carbamazepine levels, and adjust dose accordingly. </li><li>Advise the person to report symptoms of carbamazepine toxicity.</li></ul></li><li><strong>Digoxin</strong> — erythromycin increases the concentration of digoxin.<ul><li>Monitor digoxin concentration.</li></ul></li><li><strong>Drugs that prolong the QT interval (such as antiarrhythmics, antipsychotics, and tricyclic antidepressants) </strong>— macrolides can also prolong the QT interval.<ul><li>Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) also predispose to QT prolongation.</li><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia (such as diuretics, corticosteroids, short-acting beta<sub>2</sub>-agonists) </strong>— hypokalaemia is a risk factor for QT prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Ergotamine</strong> — erythromycin is predicted to increase the risk of ergotism when given with ergotamine.<ul><li>Manufacturer advises caution.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy due to cytochrome P450 enzyme CYP3A4 inhibition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">MHRA, 2014</a>].   <ul><li>For simvastatin (potent CYP3A4 inhibitor) — concurrent use is contraindicated. If erythromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin (moderate CYP3A4 inhibitor) — avoid concurrent use if possible. If erythromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment or prescribe the lowest starting dose of atorvastatin (that is 10 mg) and do not exceed 20 mg atorvastatin daily. Advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>For pravastatin — prescribe erythromycin with caution, and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — rosuvastatin is not associated with cytochrome P450 interactions, and clinically significant interaction with erythromycin is not expected for fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness. </li></ul></li><li><strong>Theophylline </strong>— erythromycin decreases the clearance of theophylline, and theophylline potentially decreases the clearance of erythromycin.<ul><li>Monitor theophylline levels. Consider a dose reduction of theophylline if toxicity is suspected (for example if headache, nausea, or palpitations occur).</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— erythromycin increases the anticoagulant effect of warfarin.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after a course of erythromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">MHRA, 2020</a>]</p><!-- end field 444a6d00-c9f4-47ea-9266-aa9000bb2260 --><!-- end item f4792545-22f8-4bae-b604-aa9000bb2248 -->","subChapters":[]},{"id":"407c0dc8-760c-50a3-827a-83b313fd023f","slug":"use-in-pregnancy-breastfeeding","fullItemName":"Use in pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 56d51e1a-9819-49b2-8400-aaa300db15fd --><h3>Can erythromycin be used during pregnancy and breastfeeding?</h3><!-- end field 56d51e1a-9819-49b2-8400-aaa300db15fd -->","summary":"","htmlStringContent":"<!-- begin item 901e3f73-89dd-4f7c-b891-aaa300db15dc --><!-- begin field b018dda7-e5c3-4d36-a26c-aaa300db15fd --><ul><li><strong>Pregnancy</strong><ul><li>Erythromycin is not known to be harmful in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>].</li><li>Available data for erythromycin do not suggest an increased overall risk of congenital malformation or of cardiac malformations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">UKTIS, 2019</a>]. </li></ul></li><li><strong>Breastfeeding</strong><ul><li>Trace amounts of erythromycin are found in breastmilk, but it is appropriate to use in women who are breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]. The small amounts in milk are unlikely to cause adverse effects in the infant [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">LactMed, 2015</a>].</li></ul></li></ul><!-- end field b018dda7-e5c3-4d36-a26c-aaa300db15fd --><!-- end item 901e3f73-89dd-4f7c-b891-aaa300db15dc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}